Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2024
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Table of Content
1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
1.1 Product Overview and Scope of Glucagon Like Peptide-1 (GLP-1) Agonists
1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Comparison by Application: (2021-2027)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts
1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2027
1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2027
1.4.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2016 Versus 2021 Versus 2027
2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competition by Manufacturers
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2016-2021)
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Sites, Area Served, Product Type
2.5 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation and Trends
2.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue
2.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario by Region
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Region
3.5.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
3.5.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.6.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.6.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.7.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.7.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Analysis by Type
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2016-2021)
5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Analysis by Application
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Corporation Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Amylin
6.6.1 Amylin Corporation Information
6.6.2 Amylin Description and Business Overview
6.6.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.7.5 Amylin Recent Developments/Updates
7 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Cost Analysis
7.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
7.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
8.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
9 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Growth Drivers
9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
9.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
10 Global Market Forecast
10.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2022-2027)
10.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2022-2027)
10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Glucagon Like Peptide-1 (GLP-1) Agonists by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer